Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Milestone Pharmaceuticals Inc (MIST)

Milestone Pharmaceuticals Inc (MIST)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Milestone Pharmaceuticals: Q3 Earnings Snapshot

Milestone Pharmaceuticals: Q3 Earnings Snapshot

MIST : 1.7000 (-6.08%)
Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update

MIST : 1.7000 (-6.08%)
Milestone Pharmaceuticals: Q2 Earnings Snapshot

Milestone Pharmaceuticals: Q2 Earnings Snapshot

MIST : 1.7000 (-6.08%)
Milestone Pharmaceuticals: Q1 Earnings Snapshot

Milestone Pharmaceuticals: Q1 Earnings Snapshot

MIST : 1.7000 (-6.08%)
Milestone Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference

/CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced that members of its management team will participate in a fireside chat at the Piper...

MIST : 1.7000 (-6.08%)
Milestone Pharmaceuticals: Q3 Earnings Snapshot

Milestone Pharmaceuticals: Q3 Earnings Snapshot

MIST : 1.7000 (-6.08%)
Milestone Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Corporate Updates

New Drug Application submitted to the U.S. Food and Drug Administration for CARDAMYSTâ„¢, the conditionally approved brand name for etripamil nasal spray, for...

MIST : 1.7000 (-6.08%)
Milestone Pharmaceuticals Presents Positive Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR at the American Heart Association Scientific Sessions 2023

Etripamil, an investigational drug, showed statistically significant reduction in ventricular rate by 30 beats per minute for episodes of atrial fibrillation...

MIST : 1.7000 (-6.08%)
Milestone Pharmaceuticals to Host Investor and Analyst Webcast to Review Data from ReVeRA Phase 2 Study of Etripamil in AFib-RVR

/CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced that the Company will host a virtual investor and analyst webcast on Monday, November...

MIST : 1.7000 (-6.08%)
Milestone Pharmaceuticals Announces Submission of New Drug Application to the U.S. FDA for Etripamil

Submission seeks approval for treatment of an abnormal heart rhythm, Paroxysmal Supraventricular Tachycardia or PSVT Comprehensive data package includes...

MIST : 1.7000 (-6.08%)

Barchart Exclusives

Is Domino's Pizza Stock Worth Buying? Buffett Likes Its Huge Free Cash Flow
Berkshire Hathaway's new stake in Domino's Pizza stock shows that its huge free cash flow (FCF) and FCF margins are attracting value investors. Shorting out-of-the-money DPZ puts is one way to play this. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar